Communiqués Granules India Limited

Actions

GRANULES

INE101D01020

Produits pharmaceutiques

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:51 20/07/2026			Varia. 5j.	Varia. 1 janv.
875,95 ^INR	-0,47 %		-1,53 %	+46,35 %

06/07	Granules India obtient l'exclusivité du statut " First-to-File » pour la suspension orale d'oxybate de sodium à libération prolongée	MT
06/07	Granules India Limited obtient l'exclusivité " First-to-File » pour l'ANDA de l'oxybate de sodium à libération prolongée en suspension orale	CI

Communiqués

29/04	Granules India : Q4FY26 Revenue from operations at INR 14,706 Mn up 23% YoY, EBITDA at INR 3,521 Mn up 40% YoY, PBT before Exceptional Item at INR 2,464 Mn up 48% YoY, PAT at INR 2,016 Mn up 33% YoY.	PU
05/03	Granules India : Packaging Facility in US gets FDA EIR with No Action Indicated Status	PU
28/01	Granules India : SERP Join Handsto Strengthen Breast Cancer Screening in Sangareddy	PU
23/01	Granules India : Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.	PU
08/01	Granules India : Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)	PU
22/12	Granules India : Pharmaceuticals Inc. Receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT®)	PU
01/12	Granules India : Strengthens RD Leadership with Two New Centres of Excellence at IIT Hyderabads Technology Research Park	PU
13/11	Granules India : Q2FY26 Revenue from operations at INR 12,970 Mn up 34% YoY, EBITDA at INR 2,782 Mn up 37% YoY, PBT at INR 1,759 Mn up 37% YoY, PAT at INR 1,306 Mn up 34% YoY.	PU
13/11	Granules India : Pharmaceuticals Receives EIR Following Successful US FDA PreApproval Inspection	PU
13/11	Granules India : Life Sciences Receives First U.S. FDA Approval for Hyderabad Facility	PU
30/10/25	Granules India : Unit I Facility Secures US FDA EIR with ‘Voluntary Action Indicated’ (VAI)	PU
05/09/25	Granules India : and NIPER S.A.S Nagar Launch Centre of Excellence for Sustainable Pharma Innovation	PU
12/08/25	Granules India : First QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFouth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth QuarterFirst QuarterSecond QuarterThird QuarterFourth Quar	PU
12/08/25	Granules India : Q1FY26 Revenue from operations at INR 12,101 Mn up 3% YoY, EBITDA (before exceptional items) at INR 2,467 Mn down 5% YoY	PU
12/08/25	Granules India : and IIT Hyderabad Establish “Dr Krishna Prasad Chigurupati Chair Professorship” in Process Automation	PU
28/05/25	Granules India : Q4FY25 Revenue from operations at INR 11,974 Mn up 2% YoY, EBITDA at INR 2,524 Mn down 1% YoY, PAT at INR 1,520 Mn up 17% YoY	PU
17/04/25	Deal Ticker: Granules India Acquires Senn Chemicals AG	AQ
11/04/25	Granules India : Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services	PU
24/02/25	Granules India : enters CDMO business by acquiring Senn Chemicals AG	PU
24/01/25	Granules India : Quarterly Results FY25 Q3	PU
17/12/24	Granules India : Announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.	PU
04/12/24	Granules India : Confirms USFDA Classification Does Not Impact Ongoing Operations, Assures Commitment to Compliance and Growth	PU
27/11/24	Granules India : ’ Net Zero Commitment Validated and Approved by Science Based Targets Initiative	PU
08/11/24	Granules India : Unit V Facility Secures US FDA EIR with ‘No Action Indicated’ Status	PU
06/11/24	Granules India : Quarterly Results FY25 Q2	PU